ALK and non-small cell lung carcinoma: Therapy with crizotinib has significant clinical activity in patients with non-small cell lung cancer (NSCLC), anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT) that harbor ALK rearrangements (Kwak et al., 2010; Mossé et al., 2013).